De novo pure erythroid leukemia with rapid progression harboring EZH2 and TP53 frameshift mutations: A case Report
Due to the unclear pathogenesis of PEL and the lack of targeted therapeutic drugs, the prognosis is inferior. Further research into the signaling pathways regulated by the identified mutations and their potential as therapeutic targets is essential to improve the prognosis of this aggressive form of leukemia.
Authors
- Kun Chen (ORCID: https://orcid.org/0000-0001-8232-1569)
- Xiangyu Li (ORCID: https://orcid.org/0000-0003-4650-5517)
- Huanhuan Qin
- Zhiguang Lin
Institutions
- Fudan University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1097/md.0000000000039766
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00